Shots:

•  Sierra will pay $3M upfront and ~$195M milestone payments to Gilead and additional royalties from mid-teen-to-high-twenties on net sales
• Sierra will continue all currently ongoing clinical studies with Momelotinib following a transition period
• Momelotinib (a JAK 1/2 and ACVR1 Inhibitor) is in Phase III- has being administered to ~1200 patients- since 2009- and is expected to get patent exclusivity in EU and U.S. till 2033 and 2035 respectively  

     Ref: Sierraoncology | Image:  Sierra oncology